Suzanne E. Schindler

The U.S. Is Funding Fewer Grants in Every Area of Science and Medicine (Gift Article) A quiet policy change means the government is making fewer bets on long-term science.

The U.S. Is Funding Fewer Grants in Every Area of Science and Medicine www.nytimes.com/interactive/...

#Alzheimers #dementia #science #neuroscience #NeuroSkyence

Animated educational videos for clinicians that describe how to use biomarkers for Alzheimer's disease in clinical practice.

Neurology in Motion: practicalneurology.com/videos/neuro...

#ENDALZ #dementia

Towards pharmacological prevention of Alzheimer disease Nature Reviews Neurology, Published online: 03 November 2025; doi:10.1038/s41582-025-01154-yAdvances in biomarkers, blood tests and disease-modifying therapies have created a credible path to clinical prevention of Alzheimer disease (AD). In this Perspective, the authors discuss promising approaches to the prevention of AD and highlight strategic gaps.

ICYMI: New online! Towards pharmacological prevention of Alzheimer disease

That's exactly why Randall J. Bateman, MD, was invited to
@cbssundaymorning.bsky.social — see how our groundbreaking clinical trials could change the outcome for millions of people who live in fear of what Alzheimer’s takes from them: campaigns.med.washu.edu/alz

Alzheimer’s Association Welcomes FDA Clearance of First Blood Test for Use in Primary Care to Rule Out Alzheimer’s-Related Amyloid Pathology Developed by Roche, this is the first blood test for use in primary care to rule out Alzheimer's-related amyloid pathology.

The FDA has cleared the first blood test for Alzheimer’s for use in primary care settings to rule out the presence of amyloid.

“This is another important step toward expanding access to Alzheimer’s diagnostic tools." -Joanne Pike, Association president & CEO

Read our full statement: bit.ly/4oh3Tiu

NIH Leadership Is Failing Early Career Researchers Halted training programs, funding chaos, and hiring freezes jeopardize advancement options for early career researchers.

My op-ed just came out discussing how NIH leadership is failing early career researchers and, importantly, how we can push back and take our future into our own hands.

Has Your Scientific Work Been Cut? We Want to Hear.

Has your research funding been cut by the administration? Now is the time to raise your voices. I know we all know someone, even if we ourselves haven’t been personally affected (yet). Please share your story with @nytimes.com

www.nytimes.com/2025/10/08/c...

Congrats!

New landscape of the diagnosis of Alzheimer's disease Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individu...

New landscape of the diagnosis of Alzheimer's disease www.thelancet.com/journals/lan... by @thelancet.com

#Alzheimers #dementia #biomarkers #neuroscience #NeuroSkyence

Review of Alzheimer's diagnostics from The Lancet:

New landscape of the diagnosis of Alzheimer's disease
www.sciencedirect.com/science/arti...

#ENDALZ

We're proud to share that over the last year, we invested $112.2 million in our research programs—the largest single-year on record—bringing our total active & committed investments to over $450 million. Help us continue the momentum: alz.org/donate. #ENDALZ #BrainHealth

Impacts of Environmental Distractions and Interruptions on Unsupervised Digital Cognitive Assessments in Older Adults: Cognitive Ecological Momentary Assessment Study Background: Unsupervised cognitive assessments are becoming commonly used in studies of aging and neurodegenerative diseases. Because assessments are completed in everyday environments and without a p...

New paper from the lab. First author @mwelhaf.bsky.social, now in a TT position at North Carolina A&T. We wanted to know how environmental contexts and self-reported distractions impacted cognitive #EMA in older adults. mhealth.jmir.org/2025/1/e71578 1/n

Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks Objective The objective of this study was to evaluate the timing of change of Alzheimer's disease (AD) plasma biomarkers (Aβ42/Aβ40, p-tau217, p-tau181, GFAP, and NfL) from six different assay platf.....

"Clocks" that relate amyloid and tau PET to time were used to examine the timing of biomarker changes (including plasma biomarkers) in Alzheimer disease. Plasma Aβ42/40 changes very early! onlinelibrary.wiley.com/doi/10.1002/...

#ENDALZ

Selection and Interpretation of Biomarker Tests for Alzheimer Disease Diagnostic tests for Alzheimer disease can help guide clinical management, but results must be interpreted carefully.

Practical information for clinicians on selection and interpretation of different biomarker tests for Alzheimer disease:

practicalneurology.com/diseases-dia...

Alzheimer's disease drug development pipeline: 2025 Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinic...

Alzheimer's disease drug development pipeline: 2025 - Cummings - 2025 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

From clinical trials to practice, WashU Medicine’s Memory Diagnostic Center offers top-tier, end-to-end Alzheimer's care. Now, a promising new study paves the way for clinics worldwide to adopt our elevated standard of outpatient care and infrastructure. 🔗 medicine.washu.edu/news/drug-to...

Development of Simple Risk Scores for Prediction of Brain β-Amyloid and Tau Status in Older Adults With Mild Cognitive Impairment: A Machine Learning Approach url:https://academic.oup.com/psychsocgerontology/article-abstract/doi/10.1093/geronb/gbaf085/8125623

Protective genetic variants against Alzheimer's disease Genetic studies can offer powerful insights for the development of disease-modifying therapies for Alzheimer's disease. Protective genetic variants th…

Genetic studies reveal protective variants that delay Alzheimer's, offering insights into new therapies.

Be sure to check out our new review on protective genetic variants in Lancet Neurology, along with the editorial that features this research!

www.sciencedirect.com/science/arti...

‘I just fell to my knees and cried’: St. Louisans face devastating damage after tornado that killed 5 More than 5,000 homes were impacted, and 38 people were injured after an EF3 tornado tore across St. Louis.

UPDATE: More than 5,000 homes were impacted, and 38 people were injured after an EF3 tornado tore across St. Louis. via @stlpublicradio.bsky.social

❌ FALSE: “For 20 years…we were directing Alzheimer’s research to one hypothesis. And any other hypotheses were shut down.” - Sec. Kennedy

Over the last decade, less than 14% of new National Institutes of Health (NIH) Alzheimer’s projects focused on amyloid beta as the therapeutic target. 🧵(1/4)

Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics - Journal of Neurology The emergence of monoclonal antibody (MABs) drugs since the FDA approval of lecanemab has resulted in dramatic changes in the clinical approach and management of early-stage Alzheimer’s disease (AD). ...

The Wash U lecanemab paper is a hard act to follow. But here’s a combo experience with a private clinic and U Wash.

link.springer.com/article/10.1...

We have been trying to learn everything we can from our experiences with amyloid-targeting treatments to improve patient care. We present the findings from our first 234 patients treated with lecanemab in JAMA Neurology: ja.ma/42TLKzx

#ENDALZ
@WashUNeurology

Check out a great podcast featuring Joe Therriault
explaining how to diagnose Alzheimer's disease by integrating the clinical impression with plasma biomarkers: pca.st/episode/b729...

He makes PPV/NPV so easy to understand!

From his recent paper:
rdcu.be/eldzt

Looks awesome, have a great time!

Federal cuts to National Institutes of Health could threaten medical progress Former National Institutes of Health Director Dr. Francis Collins, who abruptly left his NIH research lab in February, fears aggressive downsizing could impact Americans’ health.

Thank you @60minutes.bsky.social for giving the NIH freezes, termination, and proposed budget cuts the attention they deserve. ALL Americans, regardless of party, will feel this impact to their health far beyond one administration. www.cbsnews.com/video/nih-cu...

Real-World Experience With Long-Term Lecanemab Treatment: A Retrospective Chart Review in Early Alzheimer's Disease A video from David Weisman, posted on Apr 17, 2025.

WIth 94 sequential patients on lecanemab, what did we learn?

www.vumedi.com/video/real-w...

We need confidence that AD treatments will benefit our patients and at this point clinical endpoints are needed. In the future we can work to validate biomarkers as surrogate outcomes. Here is a link to more discussion about these issues on Alzforum:
www.alzforum.org/news/researc...

Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers This cohort study investigates if the clinical phenotype of patients without dementia is associated with blood phosphorylated tau 217 interpretation.

Happy to share the work of Vincent Bouteloup, which has just been published in JAMA Neurology and presented this morning at the AD/PD Conference! jamanetwork.com/journals/jam...

Valiltramiprosate Demonstrates Greater Promise in Milder Forms of Alzheimer Disease, Phase 3 APOLLOE4 Study Shows Although valiltramiprosate failed to distinguish itself from placebo on the primary end point, the drug performed significantly better among mild MCI participants vs those with mild Alzheimer disease.

Big loss today. Alzheon overall trial was negative. But there were provocative findings. www.neurologylive.com/view/valiltr...